Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 3/20 | 0.38 |
| ▸ | CES1 | P23141 | 3/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.36 |
| ▸ | DGKA | P23743 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31549344 | 0.93 | ALDH1A1 (0.56) | ALDH1A1TSHRKMT2AMAPTCES2 | |
| SCHEMBL9891380 | 0.91 | ALDH1A1 (0.59) | ALDH1A1TSHRKMT2AMAPTCES2 | |
| SCHEMBL27441221 | 0.91 | ALDH1A1 (0.54) | ALDH1A1TSHRKMT2AMAPTCES2 | |
| SCHEMBL9891379 | 0.91 | ALDH1A1 (0.46) | ALDH1A1TSHRKMT2AMAPTCES2 | |
| SCHEMBL1392323 | 0.90 | ALDH1A1 (0.54) | ALDH1A1TSHRKMT2AMAPTMEN1 | |
| SCHEMBL27441231 | 0.88 | TSHR (0.45) | ALDH1A1TSHRKMT2AMAPTCES2 | |
| SCHEMBL27441229 | 0.86 | KMT2A (0.54) | ALDH1A1TSHRKMT2AMAPTCES2 | |
| SCHEMBL31549369 | 0.85 | ALDH1A1 (0.62) | ALDH1A1TSHRKMT2AMAPTDGKA | |
| SCHEMBL1520911 | 0.85 | — | — | |
| SCHEMBL27441244 | 0.84 | ALDH1A1 (0.45) | ALDH1A1TSHRKMT2AMAPTDGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2016-12-08 | — | — | US | disclosed |
| US-9212308-B2 | Liquid crystal composition, polymer/liquid crystal composite, liquid crystal element, and liquid crystal display device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| US-9212308-B2 | Liquid crystal composition, polymer/liquid crystal composite, liquid crystal element, and liquid crystal display device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | NOVO NORDISK HEALTHCARE AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-8632792-B2 | Cooling sensation agent composition and sensory stimulation agent composition | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-01-21 | — | — | US | disclosed |
| US-20120138853-A1 | LIQUID CRYSTAL COMPOSITION, POLYMER/LIQUID CRYSTAL COMPOSITE, LIQUID CRYSTAL ELEMENT, AND LIQUID CRYSTAL DISPLAY DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20110117147-A1 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-05-19 | — | — | US | disclosed |
| WO-2009123355-A2 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117147-A1 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TRPA1, HRH1, HRH2 | ALDH1A1 520/4885TSHR 2479/4885KMT2A 3562/4885 |
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | GALE, GALNT2, GALNT1 | ALDH1A1 244/4885TSHR 1226/4885KMT2A 4257/4885 |
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | TGM2, TGM3, TGM1 | ALDH1A1 3543/4885TSHR 1299/4885KMT2A 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.